Phrenic Nerve Stimulation for Central Sleep Apnea

This policy addresses implantable phrenic nerve stimulation (e.g., the remedē system) for treatment of central sleep apnea (CSA), including idiopathic CSA and CSA secondary to heart failure (with Cheyne‑Stokes respiration), stroke, opioid use, high altitude, and other medical conditions. However, PNS is considered experimental/investigational and/or unproven in all situations, coverage is subject to the member’s benefit plan, and first‑line therapies (CPAP, supplemental oxygen, PAP modalities or respiratory stimulants as appropriate) should generally be attempted before considering PNS, with no explicit coverage criteria provided in this document.

"Implantable phrenic nerve stimulation for treatment of central sleep apnea (CSA)."

Sign up to see full coverage criteria, indications, and limitations.